FDA clears Roche’s bis­pe­cif­ic Eylea con­tender, but can it com­pete with the Re­gen­eron block­buster?

The FDA fi­nal­ly ap­proved Roche-Genen­tech’s Eylea ri­val late Fri­day, al­though pre­cise­ly how much the long-act­ing an­ti­body can cut in­to Re­gen­eron’s block­buster sales re­mains un­clear.

The new drug, known chem­i­cal­ly as faricimab and now mar­ket­ed as Vabysmo, was OK’d for use in di­a­bet­ic mac­u­lar ede­ma and wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, one of the lead­ing caus­es of blind­ness in old­er Amer­i­cans. Re­gen­eron has dom­i­nat­ed the dual mar­kets for near­ly a decade with Eylea, an pro­tein in­ject­ed once every 8 or 12 weeks.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.